Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT01446744
PHASE2

Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET)

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

View on ClinicalTrials.gov

Summary

Stereotactic Ablative Radiotherapy (SABR) is a new radiation treatment that delivers high-dose, precise radiation to small tumors in 1-3 weeks of treatment. This new technique can potentially allow radiation treatments to be focused more precisely, and delivered more accurately than with older treatments. This improvement could help by reducing side effects and by improving the chance of controlling the cancer by more precisely treating the cancer. The purpose of this study is to compare SABR with current approaches of chemotherapy and conventional radiotherapy to assess the impact on overall survival and quality of life.

Official title: Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): A Randomized Phase II Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

99

Start Date

2011-11

Completion Date

2026-06

Last Updated

2023-10-05

Healthy Volunteers

No

Interventions

RADIATION

Stereotactic ablative radiotherapy

Total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks.

RADIATION

palliative radiotherapy

Investigators should follow the principles of palliative radiotherapy as per the individual institution. Treatment recommendations are as follows: Brain: Whole brain radiotherapy i.e. 20 Gy in 5 fractions, 30 Gy in 10 fractions Lung: Palliative radiotherapy as per 2011 consensus guidelines.15 i.e. 8 Gy in 1 fraction, 20 Gy in 5 fractions, 30 Gy in 10 fractions Bone: Palliative radiotherapy as per 2011 consensus guidelines.16 i.e. 8 Gy in 1 fraction (most common), 20 Gy in 5 fractions, 30 Gy in 10 fractions Liver: 20 Gy in 5 fractions if standard institutional practice

Locations (10)

Alfred Health, William Burkland Radiotherapy Centre

Melbourne, Victoria, Australia

BC Cancer Agency

Vancouver, British Columbia, Canada

Atlantic Clinical Cancer Research , QEII Health Sciences Centre

Halifax, Nova Scotia, Canada

Juravinski Cancer Centre, Hamilton Health Sciences

Hamilton, Ontario, Canada

London Regional Cancer Program of the Lawson Health Research Institute

London, Ontario, Canada

Ottawa Cancer Centre

Ottawa, Ontario, Canada

PEI Cancer Treatment Center

Charlottetown, Prince Edward Island, Canada

McGill University Health Centre Research Institute

Montreal, Quebec, Canada

VU University Amsterdam (VUmc)

Amsterdam, Netherlands

The Beatson West of Scotland Cancer Centre

Glasgow, United Kingdom